Dean Felsher
机构: Professor of Medicine-Oncology, Pathology, Stanford University
每年引用次数
引用次数
引用: 24,248
H-指数: 73
I10-指数 : 154
出版物: 355
Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance
Zhongwei Cao , Bi-Sen Ding , Peipei Guo , Sharrell B. Lee
Cancer Cell 25 ( 3) 350 -365
142
2014
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.
Yulin Li , Peter S. Choi , Stephanie C. Casey , David L. Dill
Cancer Cell 26 ( 2) 262 -272
182
2014
MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells
Brian J. Altman , Annie L. Hsieh , Arjun Sengupta , Saikumari Y. Krishnanaiah
Cell Metabolism 22 ( 6) 1009 -1019
134
2015
Tumor dormancy and oncogene addiction.
DEAN W. FELSHER
Apmis 116 629 -637
33
2008
c‐Myc, MHCI, and NK Resistance in Immunodeficiency Lymphomasa
JONATHAN BRAUN , DEAN W. FELSHER , LEE A. GOODGLICK
Annals of the New York Academy of Sciences 651 ( 1) 467 -469
2
1992
A novel octamer regulatory element in the VH11 leader exon of B-1 cells.
D W Felsher , L Goodglick , J Braun , M S Neshat
Journal of Immunology 154 ( 9) 4546 -4556
4
1995
STK38 is a critical upstream regulator of MYC’s oncogenic activity in human B-cell lymphoma
B C Bisikirska , S J Adam , M J Alvarez , P Rajbhandari
Oncogene 32 ( 45) 5283 -5291
77
2013
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas
D W Felsher , J Cavaillé , H Prats , G Delsol
Leukemia 25 ( 12) 1882 -1890
125
2011
Pharmacological inactivation of MYC for the treatment of cancer.
D.W. Felsher , N. Bradon
Drug News & Perspectives 16 ( 6) 370 -374
16
2003
R15 – Oral miR-16 participe à l’angiogenèse des tumeurs exprimant l’oncogène de fusion X-ALK
E. Dejean , M.H. Rénalier , M. Foisseau , X. Agirre
Bulletin du Cancer 97 ( 4) S22
1
2010
Human embryonic stem cells exhibit altruistic behavior in the microenvironment of oxidative stress
B. Das , R. Tsuchida , R. Bayat-Mokhtari , D.W. Felsher
Cytotherapy 15 ( 4)
2013
MYC Potentiates DNA Damage Response Dependent Cellular Senescence
P.T. Tran , J. Chen , P. Choi , G. Horng
International Journal of Radiation Oncology Biology Physics 72 ( 1)
2008
Twist1 Overexpression Induces Increased Tumor Cell Aggressiveness and Resistance to Sorafenib in Hepatocellular Carcinoma Cells
A. Wild , D. Bellovin , S.T. Chettiar , N. Gandhi
International Journal of Radiation Oncology*Biology*Physics 87 ( 2) S659
2013
Predictive Modeling of Tumor Regression Kinetics Using a Murine Model of Oncogene-Addicted Lung Cancers
P.T. Tran , J. Lin , P. Bendapudi , S. Koh
International Journal of Radiation Oncology Biology Physics 69 ( 3)
2007
RAS and BCL-2 co-operate in a mouse model of myelodysplasia (MDS).
Ghulam Mufti , S Muszlak , D Felsher , S Kogan
Blood 102 ( 11)
2003
SU‐FF‐J‐162: In Vivo Biological Evaluation of Micro‐CT Based 3D Conformal Radiotherapy System
G Nelson , M Rodriguez , H Zhou , A Lee
Medical Physics 36 ( 6) 2514 -2514
2009
Generation and characterization of murine Ly-1 (CD5) B-cell lines
Jonathan Braun , Dale Ando , K Denis , D Felsher
B-Cell Development: UCLA Symposia in Molecular and Cellular Biology. New York, Alan R Liss 55
4
1988
Dissection of the role of the tumor microenvironment in oncogene addiction by ex vivo and in situ imaging
L Tong , J Jeon , B Shen , R Jianghong
JOURNAL OF NUCLEAR MEDICINE 54 25 -25
2013
Conditional NPM-ALK and TPM3-ALK transgenic mice
S Giuriato , D Felsher , At Saati , C Demur
BULLETIN DU CANCER 95 S28 -S28
2008
Identification of proteomic changes in signaling upon oncogene inactivation after therapeutic treatment in hematopoietic tumors using a novel nanoscale-immunoassay system
D Felsher
ANNALS OF ONCOLOGY 19 200 -200
2008